Ultragenyx Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Leveroni Court Novato CA United States of America 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
Ultragenyx: Undervalued Ahead Of Two FDA Decisions
Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up Following Strong Earnings
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Brazilian Rare Earths June 2026 Quarterly Report
Fifth Third Bancorp Acquires New Holdings in Ultragenyx Pharmaceutical Inc. $RARE
LEADING EDGE MATERIALS ADVANCES MIDSTREAM PROCESSING STRATEGY FOR THE NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity